TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction of decline in pulmonary function (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: remission as measured by HAM-D21 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of malaria parasites in blood spot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Subjective rating of Gunnar computer glasses preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cranial or Caudal bladder base displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Vertical and horizontal bladder neck displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quantification of residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angiographic in-lesion binary restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentration of melatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Violence risk scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative change in Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of eyes with wound leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Attitude towards IV iron treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: calcium homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reported Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change of BMD (Bone mineral density)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractures and fallings
Endpoint domain: Adverse events/effects
Primary endpoint: Overall early complications
Endpoint domain: Adverse events/effects
Primary endpoint: Diaphragm electromyography (EMGdi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dyspnea intensity measured by the 10-point Borg Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale (MADRS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Survival without occurrence of status epilepticus
Endpoint domain: Mortality/survival
Primary endpoint: 2 seizures with consciousness impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Need to add a second antiepileptic drug (AED)
Endpoint domain: Adverse events/effects
Primary endpoint: Uncorrected distance and near vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Engagement in Decision Making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Illness-related Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived Self-efficacy in Patient-physician Interactions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-treatment Regret
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive Change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HSV-2 Prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentages of Subjects With Seroconversion or Significant Increase in HI Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages of Subjects Who Achieved HI Titer ≥40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants who completed fecal testing and colonoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diagnoses of colorectal Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Polypectomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Characterisation of muscle connective tissue derivatives - structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Characterisation of muscle connective tissue derivatives - function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total Cell Count of Neutrophils in BAL Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Muscle biopsy parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viability on primary ALL samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in P2Y12 Reaction Units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of TIMI Major Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Morbidity of LITT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of LITT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor Marker Evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: serum levels of mannose-binding lectin (MBL) protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum levels of sirtuin-1 (SIRT1) protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual Patient Overall Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cardiac Ventricular Repolarization (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: periprocedural glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Circulating tumor cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in fronto-striatal functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: System usability score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: lower limb blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Feasibility of opportunistic salpingectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability from patients of opportunistic salpingectomy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in quantitative EEG values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ALD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positivity for diabetes-associated autoantibodies and/or clinical type 1 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiovascular Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Drug Abuse Screening Test (DAST-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Surface Area and Thickness of Subcortical Structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Diffusion values of white matter Tracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Differences in developmental Quotient / Neuropsychological scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Patients in CR After Induction Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Clinical Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Experienced Significant Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Negative predictive value of PET/CT imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Periodontal Attachment Level (PAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver function test (aspartate aminotransferase and alanine aminotransferase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corticosteroid-sparing treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from vein puncture to seldinger guide placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Late effects of proton therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in Headache Frequency
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Difference between Concern and Well-being score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-dry needling pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Spot UV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline Spot Polarization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline Skin Tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of JNJ-49122944
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve From Time 0 to Last Quantifiable Time (AUClast) of JNJ-49122944
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean log10 viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Terminal phase half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma biological markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Any Bone Fracture (FABF) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: B1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voiding difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Volume and frequency of paracentesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental glucose peaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: post prandial glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incremental area under the curve (iAUC) for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: retinal reattachment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodex balance system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morse Fall Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Mindful Attention and Awareness Scale (MAAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bone micro-architecture and strength changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Response rate to Velcade™
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruited lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in diabetes-specific empowerment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes from baseline in ECG variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum vaginal contraction pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response Through 1 Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal clinical laboratory tests
Endpoint domain: Adverse events/effects
Primary endpoint: Peak Inspiratory Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Autonomy and mobility assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: User experience assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: End tidal CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean change in ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants who complete planned maintenance PLEX regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Annualized clinical relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clavien score (> grade 1)
Endpoint domain: Adverse events/effects
Primary endpoint: ctDNA as a dynamic biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement 1
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Best visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refraction results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of hepatitis B surface antigen (HBsAg) seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of infants with APGAR score < 4 at 1 min or < 7 at 5 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Child Body Mass Index (BMI Z-score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adhesion formation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with VRE
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in event-related brain potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Flow-mediated Vasodilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Survey completion ratio
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite score of inpatient stroke care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effects on the immune system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in DAS28 From Baseline to Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With EULAR Response at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Remission According to DAS28 at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants classified on the NIAID ordinal scale
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With TEAEs in the Open-Label Extension Period
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Time Spent Sedentary
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hospitalization and nursing home placement
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of patients with left ventricle dysfunction (hypokinetic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with acute cor pulmonale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bruininks-Oseretsky Test of Motor Proficiency (BOTMP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peabody Development Motor Scales, subtest fine motor (PDMS-Ⅱ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adverse events associated with QAK423
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Hemoglobin (Hgb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: bacterial microbiological profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of subjects meeting Ramsay sedation score of 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: electromyography response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: intracranial pressure (ICP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean duration and severity of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory Area Under the Curve (AUC) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Identify progressors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in Fugl-Meyer Upper Extremity (FM-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Fugl-Meyer Motor Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With One or More Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinued Study Drug Due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in plasma concentrations of paroxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma concentration of AVP-786
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma concentration of duloxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of VLUs healed by week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in High-Density Lipoprotein (HDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline spatial and temporal gait analysis at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline postural stability at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New onset type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-adherent days generated with the new system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood perfusion value in the recipient bed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Seizures
Endpoint domain: Adverse events/effects
Primary endpoint: Standard Patient Evaluation of Eye Dryness (SPEED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of napabucasin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of probe drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessment using BPI Q9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global assessment of clinical utility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective Response Rate (Complete Response/Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Each Score on WHO 7-point Outcome Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Consistency of TMB value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Annexin A5 resistance assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar Ridge Width Gain (ARWG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes